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Introduction
Although the therapy for Behçet’s disease (BD) has
improved since infliximab was approved for refractory
retinochoroiditis therapy in Japan, the exact pathogen-
esis of BD remains unclear. Our recent genome-wide
association study has identified the IL10 and IL23R-
IL12RB2 loci as susceptibility genes for BD, in addition
to HLA-A*26 and B*51. rs1495965 is located in the
intergenic region between IL23R and IL12RB2 and
rs1800872 is located in the promoter region of IL10.
IL-10 is an anti-inflammatory cytokine that may have
multiple effects in immunoregulation and inflamma-
tion. It is thought that regulatory T cell function
related to IL-10 is an important factor in the disease
pathogenesis.
Objectives
To examine the association of IL23R-IL12RB2 and
IL10 gene polymorphisms and HLA typing with clini-
cal presentation of BD, and to examine the expression
levels of IL10 mRNA, IL23R mRNA, and IL12RB2
mRNA from PBMCs from each genotype in healthy
controls.
Methods
A total of 464 patients with BD enrolled in our recent
genome-wide association study were investigated for
association between clinical manifestations and 4 sus-
ceptibility loci, rs1495965, rs1800872, HLA-A*26, and
HLA-B*51. In our cohort, 196 patients had complete BD
and 268 patients had incomplete BD. The expression
levels of IL10 mRNA, IL23R mRNA, and IL12RB2
mRNA were examined in 33 healthy controls by real-
time PCR.
Results
The frequency of complete BD was significantly
increased in patients with the risk allele of rs1800872
under genotypic and recessive models (p=0.0004, 0.0003,
respectively). The frequency of skin lesions, ocular
lesions, and genital ulcers was also increased in patients
homozygous for the risk allele of rs1800872 (p=0.02,
0.05, 0.05, respectively). HLA-A*26, HLA-B*51, and the
rs1495965 risk allele showed no association with the fre-
quencies of complete or incomplete BD or specific clini-
cal findings. The frequency of patients with refractory
chorioretinal uveitis treated with infliximab was signifi-
cantly increased among the risk allele carriers of
rs1495695 and rs1800872 (p=0.01, 0.02, respectively).
The expression level of IL10 mRNA was significantly
decreased in the homozygotes for the rs1800872 risk
allele. There were no significant differences in the
expression levels of IL23R mRNA and IL12RB2 mRNA
among rs1495695 risk allele carriers.
Conclusion
This study suggests that the IL10 polymorphism associ-
ates with complete BD and the IL23R-IL12RB2 and IL10
gene polymorphisms associate with the severity of uvei-
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